Skip to Content
Merck
CN

SML2956

Nalmefene Hydrochloride

≥98% (HPLC), μ-opioid receptor agonist, powder

Synonym(s):

(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol hydrochloride, NIH 1036, Nalmefene HCl

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C21H25NO3·HCl
CAS Number:
Molecular Weight:
375.89
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Nalmefene Hydrochloride, ≥98% (HPLC)

InChI

1S/C21H25NO3.ClH/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H/t16-,19+,20+,21-;/m1./s1

SMILES string

C=C1CC[C@@]2(O)[C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]1OC5=C(C=C4)O.Cl

InChI key

GYWMRGWFQPSQLK-OPHZJPRHSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

Related Categories

Biochem/physiol Actions

naltrexone analogue; inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor
Nalmefene hydrochloride, a naltrexone analogue, is an inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor. Nalmefene hydrochloride is used as treatment for addiction.

pictograms

Skull and crossbonesEnvironment

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 1 - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Karl Mann et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26(12), 1941-1949 (2016-11-16)
Nalmefene, a mu- and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-opioid receptor (KOR) agonist, is approved in the European Union and other countries for the reduction of alcohol consumption in alcohol dependent patients with a high drinking risk
Javier Calleja-Conde et al.
British journal of pharmacology, 173(16), 2490-2505 (2016-05-31)
The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. Using operant alcohol self-administration
Bernadett I Gál et al.
Frontiers in pharmacology, 10, 1087-1087 (2019-10-16)
Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder (AUD) by the European Medicines Agency. While the cellular effects of nalmefene have been thoroughly investigated, data are very limited on how this agent influences neural signals associated with

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service